Caplin Point Laboratories Ltdte (BSE: 524742) is a Chennai, Tamil Nadu-based company in the Pharmaceuticals industry. With a market capitalisation of ₹16,891 Cr, it ranks #390 by market cap among the 6,189 Indian listed companies on FinBizNet, and #6 of 63 in Pharmaceuticals. At ₹2,222.15 (as of 26 Oct 2026), the share price is 25.7% below its 52-week high of ₹2,990.00 and 48.1% above its 52-week low of ₹1,500.30. The share price is up 10.3% over one year and down 9.9% over three months.
| Current Price | ₹2,222.15 |
|---|---|
| Market Cap | ₹16,891 Cr |
| BSE Code | 524742 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 26.4 |
| Return on Equity | 19.94% |
| Return on Assets | 11.97% |
| 52-Week Range | ₹1,500.30 – ₹2,990.00 |
| 1-Year Price Change | +10.3% |
| 3-Month Price Change | -9.9% |
| Beta (1Y) | 0.48 |
| Dividend Yield | 0.36% |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.caplinpoint.net |
| Revenue | ₹610 Cr |
|---|---|
| Net Profit | ₹179 Cr |
| Net Margin | 29.3% |
| EPS (Basic) | ₹23.27 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
1. Pharmaceutical Formulations-This segment produces, develops, markets, and exports generic formulations and branded products. It provides liquid injections, lyophilised injections, opthalmic products, liquid orals, capsules, tablets, softgel capsules, suppositories and ovules, dry syrups, topicals, inhalers, IV infusion products, dermo cosmetics, and other products, as well as powders for injection.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹53,132 Cr | 34.2 | 34.46% | ₹1,814 Cr | -16.1% |
| Ajanta Pharma Limited | ₹41,028 Cr | 38.9 | 25.39% | ₹1,626 Cr | +36.3% |
| Emcure Pharmaceuticals Ltd | ₹33,581 Cr | 36.3 | 19.57% | ₹2,580 Cr | +31.1% |
| Piramal Pharma Ltd | ₹25,398 Cr | -77.7 | -4.00% | ₹2,270 Cr | -1.6% |
| RUBICON RESEARCH LIMITED | ₹23,578 Cr | 93 | 19.14% | ₹534 Cr | — |
| Caplin Point Laboratories Ltdte | ₹16,891 Cr | 26.4 | 19.94% | ₹610 Cr | +10.3% |
| Pfizer Ltd. | ₹16,525 Cr | 22.9 | 17.16% | ₹653 Cr | -32.1% |
| Eris Lifesciences Ltd | ₹15,199 Cr | 24.2 | 18.07% | ₹873 Cr | -30.8% |
| Astrazeneca Pharma India Ltd. | ₹14,970 Cr | 79.8 | 22.82% | ₹683 Cr | -34.5% |
Listed by market capitalisation. Ratios are shown for context only.
Caplin Point Laboratories Ltdte is trading at ₹2,222.15, with a market capitalisation of ₹16,891 Cr.
Caplin Point Laboratories Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Caplin Point Laboratories Ltdte has a P/E of 26.4 and a return on equity of 19.94%.
Caplin Point Laboratories Ltdte is listed on the BSE under the scrip code 524742.
Caplin Point Laboratories Ltdte's share price is up 10.3% over one year and down 9.9% over three months. Its 52-week range is ₹1,500.30 to ₹2,990.00.
In Q1 FY27, Caplin Point Laboratories Ltdte reported revenue of ₹610 Cr and net profit of ₹179 Cr, with basic EPS of ₹23.27 (consolidated, parsed from the company's exchange filing).
Data as of 26 Oct 2026. Descriptive market data only — not investment advice.